secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001193125-23-295457
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics appoints Christi Shaw, former Kite CEO, to board of directors
-------------------------------------------------------------------------------

- Board expanded from 7 to 8 members; Shaw appointed as Class III director with term until 2026.
- Shaw brings over 30 years biopharma experience, most recently CEO of Kite (Gilead) until March 2023.
- Previously held senior roles at Lilly, Novartis, and Johnson & Johnson; currently on Avantor board.
- Shaw will receive compensation per company's non-employee director policy dated March 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312523295457/0001193125-23-295457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312523295457/d523217d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-295457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer